Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Frankfurt - Delayed Quote EUR

Futura Medical plc (GYX.F)

Compare
0.0900
+0.0085
+(10.43%)
As of 8:04:41 AM GMT+2. Market Open.
Loading Chart for GYX.F
  • Previous Close 0.0815
  • Open 0.0900
  • Bid 0.0935 x --
  • Ask 0.1270 x --
  • Day's Range 0.0900 - 0.0900
  • 52 Week Range 0.0760 - 0.4640
  • Volume 200
  • Avg. Volume 3,443
  • Market Cap (intraday) 34.64M
  • Beta (5Y Monthly) 1.14
  • PE Ratio (TTM)
  • EPS (TTM) 0.0000
  • Earnings Date Apr 15, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Futura Medical plc research, develops, and sells pharmaceutical and healthcare products for sexual health. Its lead product is Eroxon, a topical gel for the treatment of erectile dysfunction. Futura Medical plc was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.

www.futuramedical.com

12

Full Time Employees

December 31

Fiscal Year Ends

Recent News: GYX.F

View More

Performance Overview: GYX.F

Trailing total returns as of 4/16/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

GYX.F
75.00%
FTSE 100 (^FTSE)
0.60%

1-Year Return

GYX.F
77.27%
FTSE 100 (^FTSE)
5.14%

3-Year Return

GYX.F
74.72%
FTSE 100 (^FTSE)
7.95%

5-Year Return

GYX.F
25.00%
FTSE 100 (^FTSE)
46.08%

Compare To: GYX.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GYX.F

View More

Valuation Measures

Annual
As of 4/15/2025
  • Market Cap

    34.03M

  • Enterprise Value

    26.36M

  • Trailing P/E

    17.11

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.57

  • Price/Book (mrq)

    2.38

  • Enterprise Value/Revenue

    1.63

  • Enterprise Value/EBITDA

    16.62

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -44.68%

  • Return on Assets (ttm)

    -26.59%

  • Return on Equity (ttm)

    -47.43%

  • Revenue (ttm)

    8.4M

  • Net Income Avi to Common (ttm)

    -3.75M

  • Diluted EPS (ttm)

    0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.92M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -3M

Research Analysis: GYX.F

View More

Company Insights: GYX.F

Research Reports: GYX.F

View More